Cyclooxygenase-2 genotype and rheumatoid arthritis

Journal of Rheumatology

Volumn 33, Issue 7, 2006, Pages 1231-1234

  Lee, Kyu Hoon ^a   Kim, Hee Sang ^b   El Sohemy, Ahmed ^c   Cornelis, Marilyn C ^c   Uhm, Wan Sik ^a   Bae, Sang Cheol ^a,d  

^a Hanyang University Hospital for Rheumatic Diseases   (South Korea)

^b Kyung Hee University   (South Korea)

^c UNIVERSITY OF TORONTO   (Canada)

^d Hanyang University Medical Center   (South Korea)

Author keywords

Cyclooxygenase 2; Korea; Polymorphism; Rheumatoid arthritis; Shared epitope

Indexed keywords

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; HLA ANTIGEN; PROSTAGLANDIN E2; THROMBOXANE A2;

ADULT; AGED; ARTICLE; CALCULATION; CONFIDENCE INTERVAL; CONTROLLED STUDY; COX 2 GENE; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME ANALYSIS; EPITOPE MAPPING; FEMALE; GENE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; KOREA; MAJOR CLINICAL STUDY; MALE; PATHOLOGICAL ANATOMY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RHEUMATOID ARTHRITIS; RISK;

ADULT; AGED; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; CYCLOOXYGENASE 2; EPITOPES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEALTH STATUS; HUMANS; KOREA; MALE; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 33745783501     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. MacGregor AJ, Sneider H, Rigby AS, et al. Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum 2000;43:30-7.
2. Gao XJ, Olsen NJ, Pincus T, Stastny P. HLA-DR alleles with naturally occurring amino acid substitutions and risk for development of rheumatoid arthritis. Arthritis Rheum 1990;33:939-46.
3. Moreno I, Valenzuela A, Garcia A, Yelamos J, Sanchez B, Hernanz W. Association of the shared epitope with radiological severity of rheumatoid arthritis. J Rheumatol 1996;23:6-9.
4. Lee HS, Lee KW, Song GG, Kim HA, Kim SY, Bae SC. Increased susceptibility to rheumatoid arthritis in Koreans heterozygous for HLA-DRB 1*0405 and *0901. Arthritis Rheum 2004;50:3468-75.
5. MacGregor A, Ollier W, Thomson W, Jawaheer D, Silman A. HLA-DRB 1*0401/0404 genotype and rheumatoid arthritis: increased association in men, young age at onset, and disease severity. J Rheumatol 1995;22:1032-6.
6. Vane JR, Bakhle YS, Bolting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998;38:97-120.
7. Dubois RN, Abramson SB, Crofford L, et al. Cyclooxygenase in biology and disease. FASEB J 1998;12:1063-73.
8. Siegle I, Klein T, Backman JT, Saal JG, Nusing RM, Fritz P. Expression of cyclooxygenase 1 and cyclooxygenase 2 in human synovial tissue: differential elevation of cyclooxygenase 2 in inflammatory joint disease. Arthritis Rheum 1998;41:122-9.
9. Sano H, Hla T, Maier JA, et al. In vivo cyclooxygenase expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis and rats with adjuvant and streptococcal cell wall arthritis. J Clin Invest 1992;89:97-108.
10. Kang RY, Freire-Moar J, Sigal E, Chu CO. Expression of cyclooxygenase-2 in human and an animal model of rheumatoid arthritis. Br J Rheumatol 1996;35:711-8.
11. Woods JM, Mogollon A, Amin MA, Martinez RJ, Koch AE. The role of COX-2 in angiogenesis and rheumatoid arthritis. Exp Mol Pathol 2003;74:282-90.
12. Cha HS, Ahn KS, Jeon CH, Kim J, Koh EM. Inhibitory effect of cyclo-oxygenase-2 inhibitor on the production of matrix metalloproteinases in rheumatoid fibroblast-like synoviocytes. Rheumatol Int 2004;24:207-11.
13. Fenton C, Keating GM, Wagstaff AJ. Valdecoxib: a review of its use in the management of osteoarthritis, rheumatoid arthritis, dysmenorrhoea and acute pain. Drugs 2004;64:1231-61.
14. Papafili A, Hill MR, Brull DJ, et al. Common promoter variant in cyclooxygenase-2 represses gene expression: evidence for a role in the acute-phase inflammatory response. Arterioscler Thromb Vasc Biol 2002;22:1631-6.
15. Cipollone F, Patrono C. Cyclooxygenase-2 polymorphism: putting a brake on the inflammatory response to vascular injury? Arterioscler Thromb Vasc Biol 2002;22:1516-8.
16. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
17. Bae S-C, Cook EF, Kim SY Psychometric evaluation of a Korean Health Assessment Questionnaire for clinical research. J Rheumatol 1998;25:1975-9.
18. Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. JAMA 1949;140:659-62.
19. Jones CE, Rousseau RJ, Maxwell KW. Quantitation of rheumatoid factor activity by nephelometry. Am J Clin Pathol 1979;72:432-6.
20. Bignon JD, Fernandez-Vina MA. Protocols of the 12th International Histocompatibility Workshop for typing of HLA class II alleles by DNA amplification by the polymerase chain reaction (PCR) and hybridization with sequence specific oligonucleotide probes (SSOP). In: Charron D, editor. Genetic diversity of HLA: functional and medical implication. Paris: EDK; 1997:584-95.
21. Kotsch K, Wehling J, Blasczyk R. Sequencing of HLA class II genes based on the conserved diversity of the non-coding regions: sequencing based typing of HLA-DRB genes. Tissue Antigens 1999;53:486-97.
22. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2. Proc Natl Acad Sci USA 1999;96:272-7.
23. Bombardier C, Laine L, Reicin A, et al. The VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-8.
24. Niederberger E, Manderscheid C, Grosch S, Schmidt H, Ehnert C, Geisslinger G. Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells. Biochem Pharmacol 2004;15:341-50.
25. Chenevard R, Hurlimann D, Bechir M, et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation 2003;107:405-9.
26. Ulrich CM, Whitton J, Yu JH, et al. PTSG2 (COX-2) -765G > C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal anti-inflammatory drugs. Cancer Epidemiol Biomarkers Prev 2005;14:616-9.